Rogers L, et al. - This study assessed if step-down therapy with long-acting beta-agonist (LABA) is superior to one without; and, if attenuating the inhaled corticosteroid (ICS) dose while maintaining LABA is noninferior to remaining on stable-ICS/LABA. Findings revealed that treatment failure was not different between the 2 step-down regimens, although there was an association between stopping LABA and decline in lung function and more hospitalizations. Overall, this inquiry yielded no evidence to support the noninferiority of reduced-ICS/LABA as compared with stable-ICS/LABA.